ibidi GmbH extends partnership with Applied BioPhysics

6 February 2006

Munich, Germany-based ibidi GmbH, a supplier of solutions for biomicroscopy, has extended its partnership with Applied BioPhysics. Under the terms of the agreement, ibidi will exclusively distribute the products of Applied Biophysics in Germany. This further strengthens the German firm's position as a service provider for systems biology, says ibidi.

Applied BioPhysics, who already distribute ibidi's mu-Slides in the USA, is focused on the ECIS technology, which allows measurement of the capacity and/or the impedance of a cell layer.

"The product lines of ibidi and Applied BioPhysics complement each another excellently. Together with ibidi's mu-Slides, the user now can visualize a certain process using optical methods and also can follow the same process in an impedance measurement," commented Ulf Radler, director of the sales division at ibidi.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight